Shandong Weigao Group Medical Polymer Company Limited (Weigao Group) disclosed on 22 September 2026 that it bought back 140,000 H shares on the Hong Kong Stock Exchange the same day. The shares were repurchased at prices between HKD 3.255 and HKD 3.265, with a volume-weighted average cost of HKD 3.2586, for a total consideration of HKD 0.46 million.

Following the transaction: • Issued share capital (excluding treasury shares) fell by 0.0031% to 4.46 billion shares. • Treasury shares increased by 140,000 to 65.81 million. • Total shares in issue remained 4.52 billion, as the repurchased shares are held in treasury and not yet cancelled.

The buyback was executed under the general mandate approved on 29 May 2026, which authorises the company to repurchase up to 446.46 million shares. To date, 8.48 million shares—equivalent to 1.90% of the shares outstanding at the time the mandate was granted—have been repurchased under this authority.

In line with Hong Kong listing rules, Weigao Group is subject to a 30-day moratorium on issuing new shares or selling treasury shares, effective until 23 October 2026.